Date: 2015-01-09
Type of information: Financing round
Company: MaaT Pharma (France)
Investors: Seventure Partners (France)
Amount: € 1 million
Funding type: financing round
Planned used: MaaT Pharma™ was co-launched as a Seventure-led project in August 2013 with its main co-founders; Chairman Pierre Belichard, serial entrepreneur and currently CEO of Enterome; CEO Hervé Affagard, who brings a strong track record of leading operations in the health sector; Joël Doré, who has been trailblazing the microbiome space over the last 30 years as a prominent scientist at INRA, and Pierre Rimbaud, MD, a recognized expert in the clinical development of microbiome-based therapeutic solutions. MaaT Pharma™’s goal is to become the leader in the gut microbiome restoration arena. The company will bring forward a proprietary product resulting in a safe and efficacious restoration of the colonic microflora. MaaT Pharma™ will use the seed round proceeds to develop a first safe and standardized microbiotherapy solution for hospital use, intended for patients suffering from treatment-induced microbial imbalance (dysbiotic enteropathies). Treating patients in a safe and efficient way with the proprietary MaaT Pharma™ microbiotherapy therapeutic solution will help eliminate gastrointestinal side-effects and will reduce the economic burden of enteropathies and their complications. It will also permit fully efficient and safe use of the existing antibiotics pharmacopeia.
Others: * On January 9, 2015, Seventure Partners, one of Europe’s leaders in financing innovation, announced its investment in MaaT Pharma™, a newly founded French microbiome company. Seventure Partners’ is the first investor in MaaT Pharma™ with a €1 million investment, and has committed to investing a further €1 million on achievement of scientific milestones. MaaT Pharma™ will be Seventure Partners’ fourth portfolio company in the microbiome field. INRA transfer, the technology transfer office of INRA (French National Institute for Agricultural Research), also becomes a shareholder in the company in this transaction.
Therapeutic area: Gastrointestinal diseases - Infectious diseases
